AstraZeneca Pty Ltd
Regulatory activities for this sponsor.
Loading...
Sponsor content
317 result(s) found, displaying 61 to 70
-
Jan-2024Prescription medicine evaluationActive ingredient: tezepelumab.
-
Jan-2024Prescription medicine evaluationActive ingredient: trastuzumab deruxtecan.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Pulmicort 0.25mg/mL nebulizer suspension.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Pulmicort 0.25 mg/ml nebuliser suspension.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Pulmicort 0.50mg/mL nebulizer suspension.
-
Australian Public Assessment Report (AusPAR)Imjudo (tremelimumab) is approved for the treatment of unresectable hepatocellular carcinoma.
-
Australian Public Assessment Report (AusPAR)Imfinzi (Durvalumab) has been approved for the treatment of unresectable hepatocellular carcinoma.
-
Australian Public Assessment Report (AusPAR)Andexxa (andexanet alfa) is provisionally approved for adult patients treated with a direct factor Xa inhibitor when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.
-
Cancellation by sponsorRequested by AstraZeneca Pty Ltd
-